Loading...

Home
Stock
JNJ

JNJ Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

Loading chart...

High

243.690

Open

242.870

VWAP

242.68

Vol

6.93M

Mkt Cap

585.58B

Low

241.360

Amount

1.68B

EV/EBITDA(TTM)

17.84

Total Shares

2.41B

EV

613.41B

EV/OCF(TTM)

25.01

P/S(TTM)

6.27

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

Show More

Events Timeline

(ET)

2026-03-10

10:00:00

Johnson & Johnson's Subsidiary Receives FDA Orphan Designation for Multiple Myeloma Treatment

2026-03-08 (ET)

2026-03-08

22:30:00

KKR Plans to Sell CoolIT Systems for Over $3B

2026-03-08

17:00:00

Dr. Vinay Prasad to Leave Agency at End of April

2026-03-05 (ET)

2026-03-05

16:00:00

Johnson & Johnson's Tecvayli and Darzalex Approved by FDA for Multiple Myeloma

2026-03-05

13:40:00

Johnson & Johnson's Janssen Biotech Receives FDA Approval for New Multiple Myeloma Treatment

2026-03-03 (ET)

2026-03-03

08:10:00

Johnson & Johnson's nipocalimaba Receives FDA Fast Track Designation

2026-02-26 (ET)

2026-02-26

15:00:00

Johnson & Johnson Reports Preliminary Results of Pasritamig with Docetaxel for Prostate Cancer

News

CNBC

Market Update: Oil Price Surge and Corporate Earnings

Oil Price Volatility: U.S. crude prices surged 4% due to reports of cargo ship attacks off Iran's coast, putting pressure on stocks and indicating ongoing geopolitical risks affecting market sentiment as the S&P 500 is set for a slightly lower open.
Oracle's Strong Earnings: Oracle's quarterly results exceeded expectations, leading to a stock price increase of over 9%, with smooth AI buildout and remaining performance obligations exceeding $500 billion, highlighting the company's robust market position and growth potential.
Kohl's Price Target Cut: Goldman Sachs lowered its price target for Kohl's from $15 to $13 while maintaining a sell rating, citing mixed quarterly results and decelerating same-store sales, reflecting challenges in the retail sector.
Nike Upgrade: Barclays upgraded Nike from hold to buy, raising the price target from $64 to $73, arguing that tariff risks have eased, and management's progress in inventory management and margin stabilization provides a solid foundation for investment.

Benzinga

FDA Approves Expanded Use of Wellcovorin for Cerebral Folate Deficiency

Drug Indication Expansion: The FDA has approved Wellcovorin (leucovorin calcium) for treating cerebral folate deficiency in both adult and pediatric patients with confirmed FOLR1 gene variants, marking a significant advancement in the treatment of rare neurological diseases.
First Treatment Option: Wellcovorin becomes the first drug specifically indicated for cerebral folate deficiency, addressing common autism-like symptoms and severe developmental delays in patients, thereby offering new hope for improving their quality of life.
Scientific Basis for Approval: The FDA's approval was based on a systematic review of the literature, including patient-level information and mechanistic data, demonstrating the drug's efficacy and safety in clinical applications, which enhances confidence in its use.
Market Impact: Although GSK no longer manufactures Wellcovorin, the expanded approval allows generic versions to carry the new indication, which is expected to drive demand in the market and enhance treatment options for patients with cerebral folate deficiency.

NASDAQ.COM

03-09NASDAQ.COM

Johnson & Johnson's AKEEGA Approved by European Commission

Drug Approval: Johnson & Johnson announced that its dual-action drug AKEEGA has been approved by the European Commission for treating adult patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, marking a significant advancement in cancer treatment.
Clinical Trial Support: The approval is supported by data from the Phase 3 AMPLITUDE trial, which demonstrated significant benefits in BRCA-mutated patients, further solidifying its application potential in high-risk patient groups.
Market Outlook: According to GlobalData's Pharma Intelligence Centre, AKEEGA is projected to generate $178 million in revenue by 2031, indicating strong growth potential for Johnson & Johnson in the prostate cancer treatment market.
Stock Performance: Johnson & Johnson's stock has traded between $141.50 and $251.71 over the past year, with the latest closing price at $240.40, reflecting positive market sentiment following the drug approval.

Marketbeat

03-09Marketbeat

Subtle Success of a Neglected Dividend ETF

Dividend Stocks and Investment Considerations: Investors are often drawn to dividend stocks based on their high yields, but it's essential to consider other factors such as the company's dividend growth history and potential challenges that may affect payouts.
Diversification through ETFs: Dividend-focused exchange-traded funds (ETFs) can provide a diversified approach to investing in dividend-paying companies, helping to balance risk and enhance stability in an investment portfolio.
Performance of DGRO ETF: The DGRO ETF, which tracks U.S. companies with a history of dividend growth, has shown strong performance, returning about 13% over the past year and offering a yield of nearly 2%.
Investment Recommendations: Analysts suggest considering a range of dividend stocks, including lesser-known firms, to ensure a well-rounded investment strategy, as they may provide stability and growth potential even in fluctuating market conditions.

NASDAQ.COM

03-08NASDAQ.COM

Strong Dividends and Innovation Drive Healthcare Stocks

Strong Dividend Record: Johnson & Johnson has raised its dividend for 50 consecutive years and expects to surpass $100 billion in sales this year for the first time, showcasing its stability and appeal to income-seeking investors amid economic fluctuations.
Innovative Product Pipeline: Johnson & Johnson is awaiting approval for its robotic-assisted surgery system, Ottava, which could serve as a significant growth driver, while the company is also conducting dozens of clinical trials to expand its pharmaceutical portfolio.
Leader in Animal Health: Zoetis has increased its dividend by 458% over the past decade, and despite facing safety concerns and competitive pressures, the launch of new products like Lenivia and Portela will support its continued growth in the pet healthcare market.
Pet Ownership Trend Among Youth: Zoetis is capitalizing on the trend of younger generations increasingly choosing to own pets over having children by introducing innovative medications like Apoquel, which is expected to further solidify its market position and drive future revenue growth.

Fool

The Investment Advantage of High-Quality Dividend Stocks

Dividend Return Comparison: A study by Hartford Funds and Ned Davis Research reveals that dividend stocks have achieved an annualized return of 9.2% from 1973 to 2024, significantly outperforming non-dividend payers at 4.31%, highlighting the long-term investment value of dividend stocks.
Microsoft's Dividend Power: Microsoft is set to pay over $27 billion in dividends over the next year, with a modest yield of 0.9%, yet its rapid growth in cloud computing and AI solutions provides robust cash flow support, ensuring substantial returns for shareholders.
ExxonMobil's Stability: ExxonMobil's annual dividend payout of $17.18 billion benefits from its integrated operating model, which helps maintain steady cash flow amid oil price fluctuations, especially with current geopolitical tensions driving prices higher, enhancing its outlook.
Apple's Dividends and Buybacks: Apple pays $15.27 billion in annual dividends and has repurchased $841 billion in stock since fiscal 2013, demonstrating strong cash flow and commitment to shareholder returns, while its pivot to subscription services is expected to further enhance future profitability.

Wall Street analysts forecast JNJ stock price to rise

20 Analyst Rating

Wall Street analysts forecast JNJ stock price to rise

13 Buy

7 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

190.00

Averages

218.50

High

240.00

Current: 0.000

Low

190.00

Averages

218.50

High

240.00

Citi

Buy

upgrade

$250 -> $274

AI Analysis

2026-03-11

New

Reason

Citi

Price Target

$250 -> $274

AI Analysis

2026-03-11

New

upgrade

Buy

Reason

Citi raised the firm's price target on Johnson & Johnson to $274 from $250 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain "healthy" despite the recent volatility, the analyst tells investors in a research note. Citi's top picks are iRhythm and Medtronic.

JPMorgan

Neutral

maintain

$225 -> $250

2026-03-05

Reason

JPMorgan

Price Target

$225 -> $250

2026-03-05

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Johnson & Johnson to $250 from $225 and keeps a Neutral rating on the shares. The firm cites its increased Tremfya estimates for the target boost. The recent ramp of Tremfya in inflammatory bowel disease has driven outperformance for the product, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JNJ

Unlock Now

Valuation Metrics

The current forward P/E ratio for Johnson & Johnson (JNJ.N) is 18.82, compared to its 5-year average forward P/E of 16.16. For a more detailed relative valuation and DCF analysis to assess Johnson & Johnson's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

16.16

Current PE

18.82

Overvalued PE

17.42

Undervalued PE

14.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

12.99

Current EV/EBITDA

15.18

Overvalued EV/EBITDA

13.87

Undervalued EV/EBITDA

12.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

4.50

Current PS

5.16

Overvalued PS

4.85

Undervalued PS

4.15

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

good shares to buy in US RIGHT NOW

Intellectia · 55 candidates

Market Cap: >= 10.00BPe Ttm: 10 - 30Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Johnson & Johnson

587.32B

Micron Technology Inc

453.70B

Coca-Cola Co

334.94B

Cisco Systems Inc

306.91B

Merck & Co Inc

289.49B

Linde PLC

221.47B

whats a big gane stock

Intellectia · 5293 candidates

Ticker

Name

Market Cap$

NVIDIA Corp

4.45T

Apple Inc

3.85T

Alphabet Inc

3.67T

Microsoft Corp

3.01T

Amazon.com Inc

2.33T

Taiwan Semiconductor Manufacturing Co Ltd

1.85T

principales acciones que paguen dividendos

Intellectia · 96 candidates

Dividend Yield Ttm: 2 - 8Dividend Payout Ratio: 20.00 - 80.00Is Index Component: GSPCDividend 5yr Cagr: >= 0

Ticker

Name

Market Cap$

Exxon Mobil Corp

642.60B

Johnson & Johnson

599.00B

Home Depot Inc

369.15B

Coca-Cola Co

345.00B

Cisco Systems Inc

313.70B

Merck & Co Inc

300.17B

Intellectia · 59 candidates

Market Cap: >= 80.00BDividend Yield Ttm: 1 - 6Net Margin: >= 5.00Return On Equity: >= 10.0%Is Index Component: GSPC, DJI

Ticker

Name

Market Cap$

JPMorgan Chase & Co

809.92B

Exxon Mobil Corp

635.43B

Johnson & Johnson

598.69B

AbbVie Inc

410.36B

Procter & Gamble Co

390.70B

Home Depot Inc

379.01B

Featured Screeners

Intellectia · 45 candidates

Market Cap: >= 20.00BEps 5yr Cagr: >= 15Pe Ttm: 15 - 30Moving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Taiwan Semiconductor Manufacturing Co Ltd

1.94T

JPMorgan Chase & Co

809.92B

Johnson & Johnson

598.69B

Micron Technology Inc

464.13B

Novartis

321.75B

HSBC Holdings PLC

320.01B

stock to buy today

Intellectia · 20 candidates

Market Cap: >= 50.00BNet Margin: >= 15.00Pe Ttm: 10 - 25Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

Anglogold Ashanti PLC

63.67B

Agnico Eagle Mines Ltd

123.28B

Canadian National Railway Co

67.41B

Newmont Corporation

138.67B

Novartis

315.82B

CSX Corp

79.31B

which are the s&p 500 companies

Intellectia · 476 candidates

Is Index Component: GSPC

Ticker

Name

Market Cap$

NVIDIA Corp

4.61T

Apple Inc

3.88T

Alphabet Inc

3.81T

Microsoft Corp

2.95T

Amazon.com Inc

2.26T

Meta Platforms Inc

1.66T

Intellectia · 86 candidates

Net Margin: >= 10.00Pe Ttm: 10 - 30Return On Equity: >= 10.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Berkshire Hathaway Inc

1.08T

JPMorgan Chase & Co

832.79B

Johnson & Johnson

590.40B

Micron Technology Inc

473.78B

Bank of America Corp

384.86B

Procter & Gamble Co

366.54B

medical and tech

Intellectia · 1801 candidates

Sector: Financial Technology (Fintech) & Infrastructure, Healthcare, Healthcare Services & Equipment, Technology, Technology EquipmentList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

NVIDIA Corp

4.57T

Apple Inc

3.88T

Alphabet Inc

3.68T

Microsoft Corp

2.97T

Taiwan Semiconductor Manufacturing Co Ltd

1.88T

Meta Platforms Inc

1.63T

what stock should I buy

Intellectia · 96 candidates

Market Cap: >= 10.00BQuarter Revenue Yoy Growth: >= 5.0%Pe Ttm: 10 - 30Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Western Digital Corp

96.32B

Micron Technology Inc

449.96B

Newmont Corporation

133.47B

Huntington Ingalls Industries Inc

16.40B

Bunge Global ltd

23.57B

Monolithic Power Systems Inc

57.14B

Whales Holding JNJ

Caisse des Dépôts et Consignations

Chickasaw Capital Management, LLC

SAMA Foreign Holdings

ARS Investment Partners, LLC

Pacific Investment Management Company LLC

GQG Partners, LLC

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Johnson & Johnson (JNJ) stock price today?

The current price of JNJ is 242.99 USD — it has decreased -0.3

What is Johnson & Johnson (JNJ)'s business?

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

What is the price predicton of JNJ Stock?

Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Johnson & Johnson (JNJ)'s revenue for the last quarter?

Johnson & Johnson revenue for the last quarter amounts to 24.56B USD, increased 9.08

What is Johnson & Johnson (JNJ)'s earnings per share (EPS) for the last quarter?

Johnson & Johnson. EPS for the last quarter amounts to 2.09 USD, increased 48.23

How many employees does Johnson & Johnson (JNJ). have?

Johnson & Johnson (JNJ) has 138200 emplpoyees as of March 12 2026.

What is Johnson & Johnson (JNJ) market cap?

Today JNJ has the market capitalization of 585.58B USD.